Remdesivir does little or nothing to prevent COVID-19 deaths ─WHO

*Remdesivir appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay

Isola Moses | ConsumerConnect

Hitherto considered one of the most promising COVID-19 treatments, the antiviral drug Remdesivir is announced to do little to prevent deaths from the damaging virus.

In a recent study by the World Health Organisation (WHO), the findings of which were posted online Thursday, October 15, Remdesivir was one of the several drugs reviewed in a research of more than 11,000 people across 30 countries.

Incidentally, the Coronavirus treatment drug was reported to be part of the experimental cocktail given to US President Donald Trump when he caught the new Coronavirus late September 2020.

WHO stated that the drug “appeared to have little or no effect on hospitalised COVID-19, as indicated by overall mortality, initiation of ventilation, and duration of hospital stay.”

It was learnt the data, which has yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that Remdesivir can reduce the duration of hospital stays for COVID-19 patients.

It is recalled that Washington (US Government) authorised the emergency use of the medicine, made by US pharmaceutical company Gilead Sciences and originally intended as a treatment for Ebola — on May 1, followed by a range of other countries and the European Union.

Kindly Share This Story